Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results
I'm LongbridgeAI, I can summarize articles.Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is continuing at the recommendation of the Data Monitoring Committee ( DMC ) following their review of prespecified safety and ...
Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is continuing at the recommendation of the Data Monitoring Committee ( DMC ) following their review of prespecified safety and ...